Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkers R. Trozzi, M. Salvi, M. Karimi, A. Minucci, G. Raspaglio, M. De Donato, M. Buttarelli, A. Piermattei, L. Vaccaro, A. Grimaldi, R. De Santis, M. Massa, F. Sillano, L. Giacò, L. Mastrantoni, V. Iacobelli, F. Camarda, M. Cesana, S. Duranti, M. C. Sassu, P. Mattogno, A. Fagotti, C. Marchetti, G. Scambia, C. Nero, D. Cacchiarelli Npj Precision Oncology, 2026 Epithelial ovarian cancer (EOC) remains the most lethal gynaecological malignancy in developed countries, with recurrence and drug resistance posing significant clinical challenges. Brain metastases (BM) from epithelial ovarian cancer, once rare, are an increasing phenomenon and are characterised by a dismal prognosis. To explore the molecular underpinnings of BM in EOC, we conducted a multimodal genomics and transcriptomics analysis of matched primary tumour and brain metastases samples from a retrospective cohort. Our findings revealed high genomic concordance between primary tumour (PT) and BM, with alterations in key pathways such as MYC (MYC Proto-Oncogene, bHLH Transcription Factor) targets, extracellular matrix remodelling, and inflammatory signalling characterizing the BM. AFP (Alpha-fetoprotein) and GFAP (Glial Fibrillary Acidic Protein) emerged as potential biomarkers from the primary lesion for BM onset, while network analysis identified MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), GDF15 (Growth Differentiation Factor 15), and S100A9 (S100 Calcium Binding Protein A9) as candidate mediators of tumour-brain crosstalk. These results offer new insights into EOC brain tropism, highlighting potential targets for therapeutic intervention and personalized patient management in the precision oncology era.
Co-targeting hallmarks of cancer for therapeutic benefit in ovarian cancer: a scoping review Valentina Iacobelli, Floriana Camarda, Gloria Anderson, Marianna Buttarelli, Luca Mastrantoni, Miriam Grazia Ferrara, Rita Trozzi, Simona Duranti, Vanda Salutari, Giulia Sabetta, Giovanni Scambia, Anna Fagotti, Camilla Nero International Journal of Gynecological Cancer, 2026 The conceptualization of cancer characteristics into 14 hallmarks is now widely adopted. Simultaneous targeting of multiple cancer hallmarks represents a promising strategy to overcome therapeutic resistance and improve clinical outcomes. This approach is particularly relevant in epithelial ovarian cancer, which remains highly lethal despite significant advances in first-line treatment. This scoping review was conducted according to Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines and included searches of Medline, Scopus, the Cochrane Library, and ClinicalTrials.gov for studies published up to September 30, 2024. To be eligible, trials were required to be phase I to III clinical trials (both completed and ongoing) enrolling patients with any histotype of epithelial ovarian cancer and to target ≥2 of the 14 cancer hallmarks. Studies were screened and data extracted independently by 3 reviewers. Out of 1461 records screened at the title and abstract level (data cutoff: September 30, 2024), 225 studies were identified, comprising 111 completed and 114 ongoing trials. The adoption of co-targeting strategies has notably increased, with a 3-fold increase in trials between 2007-2013 and 2021-2024. Among 94 trials reporting clinically meaningful benefits, the most frequent combination involved targeting "sustaining proliferative signaling" and "genome instability and mutations." In ongoing trials, 40 are focused on modulating "avoiding immune destruction." However, no clinical trials were identified for 4 of the 14 hallmarks: "unlocking phenotypic plasticity," "senescent cells," "non-mutational epigenetic re-programming," and "polymorphic microbiomes." These hallmarks remain underexplored, highlighting critical gaps and potential areas for future research. In conclusion, co-targeting approaches in epithelial ovarian cancer rely on combining genomic instability and angiogenesis inhibition with chemotherapy. Current research trends are shifting toward chemotherapy-free regimens and novel therapeutic targets, aiming to address resistance mechanisms and improve long-term outcomes.
Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer Marco Pieraccioli, Alessandra Ciucci, Christian Corti, Roberta Mastrantonio, Eleonora Kristina Scarpone, Eleonora Cesari, Alessia Piermattei, Angelo Minucci, Andrea Urbani, Floriana Camarda, Anna Fagotti, Luca Tamagnone, Giovanni Scambia, Camilla Nero, Claudio Sette Drug Resistance Updates, 2026 AIM: High grade serous ovarian cancer (HGSOC) is the most aggressive subtype of ovarian cancer. HGSOC is characterized by high inter- and intra-tumoral heterogeneity, which contributes to chemotherapy resistance. Patient-derived organoids (PDOs) are valuable preclinical models to elucidate the biology of human cancers and to test their response to treatments. This study aims at characterizing the cellular heterogeneity of PDOs and to uncover vulnerabilities of chemotherapy resistant HGSOC. METHODS: Single-cell transcriptomics of PDOs developed from biopsies of platinum-resistant and platinum-sensitive HGSOC. Chemotherapeutic treatments of HGSOC PDOs and of ascitic-derived ovarian cancer cells and immunohistochemistry analyses of tissues from independent HGSOC patients. RESULTS: HGSOC PDOs comprise subclusters of cells exhibiting different transcriptional states and patient-specific signatures. Proliferative and non-proliferative subclusters co-exist in PDOs and their relative proportion is altered by chemotherapy. Proliferative cell sub-populations exhibit expression of cell cycle and DNA damage response related genes, whereas non-proliferative sub-populations display inflammatory signatures. Furthermore, sensitivity to platinum-based treatments was inversely correlated with oxidative phosphorylation (OXHPOS) in PDOs, indicating a metabolic switch associated with chemoresistance. Accordingly, platinum-resistant PDOs and ascitic HGSOC cells show higher sensitivity to OXHPOS inhibition. We found that neoadjuvant chemotherapy (NACT) directly up-regulates oncogenic and metabolic pathways that are involved in development of recurrence, such as the MYC and OXPHOS genes. NACT also induces the expression of major histocompatibility complex type II (MHC-II) molecules. Immunohistochemistry confirmed MHC-II up-regulation in post-NACT biopsies, indicating that tumour cells mount a general antigen-presenting response upon chemotherapy, associated with recruitment of infiltrating immune cells. CONCLUSION: PDOs maintain the inter- and intra-tumoral cellular heterogeneity of HGSOC. Chemotherapy targets proliferative cell subclusters, sparing non-proliferative ones. Dependency on OXPHOS represents an actionable vulnerability in PDOs, which can be exploited to hijack chemoresistance. Sequential chemotherapy and immunotherapy may also improve clinical response of HGSOC patients.
Hereditary cancer syndromes with gynecological cancer risk: focus on prevention strategies Simona Duranti, Valentina Iacobelli, Rita Trozzi, Floriana Camarda, Arianna Panfili, Anna Fagotti, Francesco Fanfani, Claudia Marchetti, Camilla Nero Frontiers in Oncology, 2026 Background Hereditary cancer syndromes, including pathogenic variants in BRCA1/2 and mismatch-repair genes, confer a substantial risk of several malignancies, including ovarian, endometrial, and fallopian tube cancers. Given the limited efficacy of current screening strategies, particularly for ovarian cancer, a prevention-focused approach is required. This review synthesizes evidence on identification, risk stratification, surveillance, chemoprevention, and prophylactic surgery in women with inherited gynecologic cancer susceptibility, proposing a precision-prevention framework. Methods A structured search of MEDLINE, Embase, and the Cochrane Library was conducted through July 2025. Original studies, reviews, and guidelines in English were included following independent screening and full-text assessment by two authors. Results Expanded germline testing, universal mismatch-repair screening, and genomic profiling have improved carrier identification beyond family history–based criteria. Integrated counseling models enhance informed decision-making and access to care. Conventional surveillance tools show limited sensitivity; emerging strategies, including circulating tumor DNA assays and artificial intelligence, require further validation. Hormonal and anti-inflammatory agents demonstrate potential for risk reduction. Prophylactic surgery, including salpingo-oophorectomy, hysterectomy, or investigational salpingectomy with delayed oophorectomy, remains central, requiring multidisciplinary evaluation and attention to fertility, menopausal health, and patient preferences. Ethical and health-economic considerations remain critical in clinical practice and policy development. Further studies are warranted to better elucidate the potential role of liquid biopsy, microbiota, and targeted vaccination strategies. Conclusions Prevention of gynecologic cancers in genetically predisposed women requires an integrated strategy that includes comprehensive genetic assessment, risk-adapted surveillance, evidence-based risk-reduction interventions, and multidisciplinary coordination. Implementing and refining precision prevention frameworks is crucial to optimize outcomes and translate genetic risk into tailored preventive care.
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer L. Mastrantoni, F. Camarda, C. Parrillo, F. Persiani, R. Trozzi, T. Pasciuto, M. Manfredelli, A. Minucci, E. De Paolis, I. Capasso, V. Iacobelli, M.T. Perri, G.F. Zannoni, F. Fanfani, G. Scambia, C. Nero ESMO Open, 2025 BACKGROUND: The No Specific Molecular Profile (NSMP) subtype accounts for ∼30%-40% of endometrial cancer (EC), comprising a heterogeneous group of EC. PATIENTS AND METHODS: The primary outcome of this study was the prevalence of actionable genomic alterations in NSMP EC, classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT). Oncogenic and likely oncogenic alterations, pathways, and co-mutation patterns were reported. The analysis was stratified by risk group according to the European Society of Gynaecological Oncology (ESGO)-ESMO-European SocieTy for Radiotherapy and Oncology (ESTRO) guidelines. Patients with NSMP EC enrolled in the FPG500 comprehensive cancer genome profiling program (NCT06020625) were included. RESULTS: ) and PTEN with PIK3R1 (OR = 4.36, P value = 0.009). An alteration in the phosphatidylinositol-3 kinase (PI3K) pathway was found in 94% of patients in the overall population and in 98% of patients with an ESCAT tier I-III alteration. CONCLUSION: Our findings highlight potentially actionable alterations in NSMP EC patients, supporting the exploration of tailored molecular-matched therapies according to risk groups.
Prediction of germline BRCA 1/2 genes pathogenetic variants from ultrasound images of healthy ovaries: Radiogenomics as an innovative tool to prevent BRCA-related cancers (PROBE II). Camilla Nero, Francesca Ciccarone, Luca Boldrini, Giulia Baldassarri, Huong Elena Tran, Maria Teresa Giudice, Francesca Sillano, Floriana Camarda, Ida Paris, Angelo Minucci, Maria De Bonis, Iolanda Mozzetta, Tina Pasciuto, Diana Giannarelli, Vincenzo Valentini, Antonia Carla Testa, Evis Sala, Giovanni Scambia Journal of Clinical Oncology, 2025 e17561 Background: BRCA 1/2 genes mutation identification enables women to opt for effective risk-reducing surgeries. Current indications for BRCA testing based on clinical-criteria/family-history based a priori BRCA probability thresholds are ineffective as most of the carriers remain undiagnosed. We already showed the feasibility of performing a radiomic analysis of ultrasound images of normal ovaries to predict BRCA 1/2 genes status, with performances on the testing set reasonably encouraging. Moreover, we performed a cost-effective analysis showing that combining clinical criteria with the radiogenomic model would have a massive effect after only one generation in detecting carriers in the general population with only a small cost increment. The present study aims at improving the preprocessing and modelling pipeline on a larger dataset and at validating the predictive model prospectively in a multicenter study. In this abstract we will present preliminary results from the retrospective phase. Methods: We conducted a retrospective multicenter observational study aimed at collecting ultrasound images of healthy ovaries with known BRCA status. Patients referring to participating center from January until December 2023 fulfilling the following selection criteria: 1. Availability of gBRCA1/2 test results; 2. Transvaginal ultrasound performed providing at least one picture of one healthy ovary. Healthy ovaries were manually segmented on ultrasound images. Image preprocessing steps were performed for speckle noise reduction, intensities normalization and calipers’ correction. Radiomic features were extracted from the segmented ovaries and the cohort was divided into training (70%) and validation (30%) sets. Radiomics features were selected with Recursive Feature Elimination (RFE) on the training set and used for the classification of BRCA status using different Machine Learning classifiers. The performances were evaluated considering area under the receiver operating characteristics curve (AUC). Results: 481 patients (282 BRCA-mutated and 199 wild-type) were analysed. 12 statistical and textural radiomics features were selected and used for classification. The Random-Forest radiomics model shows the best performance with an AUC of 0.74 in the validation set. Conclusions: The information on BRCA carrier status may allow in the future to benefit from the reduction in the number of cancer cases and related economic savings deriving from avoiding cost of genetic testing screening-based proposed. Testing one generation with radiogenomics screening could help reducing the burden of BRCA-related cancers and provide anamnestic information for subsequent generations. Future work will integrate the radiomics predictions with age and familiarity implementing a clinical-radiomics model. Clinical trial information: NCT05769517 .
Decoding tumor evolution in advanced ovarian cancer: Proteogenomic insights before and after neoadjuvant chemotherapy. Valentina Iacobelli, Marianna Buttarelli, Enrica Martinelli, Alessia Piermattei, Giuseppina Raspaglio, Marta De Donato, Francesca Sillano, Rita Trozzi, Floriana Camarda, Tina Pasciuto, Angelo Minucci, Luca Mastrantoni, Luciano Giaco', Giulia Mantini, Eduardo Maria Sommella, Vicky Caponigro, Pietro Campiglia, Gloria Anderson, Giovanni Scambia, Camilla Nero Journal of Clinical Oncology, 2025 e17582 Background: Platinum-based neoadjuvant chemotherapy (NACT) is a cornerstone in advanced ovarian cancer (OC) treatment. However, biomarkers predictive of response and the mechanisms underlying chemoresistance remain poorly defined. The PROGENITOR study aimed to (1) identify biomarkers associated with treatment response, as measured by Chemotherapy Response Score (CRS) and platinum-free interval (PFI), and (2) elucidate pathways driving chemoresistance and tumor adaptation. Methods: Tumor samples from 39 OC patients were analyzed pre- (T0) and post-NACT (T1) using RNA sequencing and liquid chromatography-mass spectrometry. Differentially expressed genes (DEGs) and proteins (DEPs) were identified, and transcriptomic-proteomic integration was performed. Deconvolution analysis, using xCell tool, evaluated tumor microenvironment dynamics, stratified by CRS and PFI. Genomic alterations were also correlated with transcriptomic and proteomic changes. Results: Longitudinal analysis revealed significant downregulation of PKMYT1, CDK1, and UBE2C at T1, suggesting impaired cell cycle progression and the potential induction of a quiescent state, contributing to chemoresistance mechanisms, as observed in CCNE1-amplified tumors. Deconvolution analysis revealed notable shifts in the tumor microenvironment post-NACT. Cancer-associated fibroblasts (CAFs) and stromal scores increased significantly in OC patients with suboptimal response (CRS 1–2), highlighting their role in chemoresistance through extracellular matrix remodeling. Additionally, immune cell populations showed significant alterations, including reduced T-cell and natural killer cell composition, along with a decline in dendritic cells, suggesting impaired antitumor immunity. These immune-stromal alterations were more pronounced in patients with poor PFI (<6 months). Conclusions: This study suggests dependency on PKMYT1 for CDK1 inhibition and a role in chemoresistance, particularly in CCNE1-amplified tumors. The integration of multi-omics and deconvolution analysis underscores the critical roles of cell cycle dysregulation, stromal activation, and immune suppression in shaping tumor evolution under NACT. These findings provide a foundation for biomarker-driven therapeutic strategies targeting cell-cycle machinery.
POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single-center cohort Camilla Nero, Rita Trozzi, Federica Persiani, Simone Rossi, Luca Mastrantoni, et al. Cancer, 2025 BACKGROUND: To date, 11 DNA polymerase epsilon (POLE) pathogenic variants have been declared "hotspot" mutations. Patients with endometrial cancer (EC) characterized by POLE hotspot mutations (POLEmut) have exceptional survival outcomes. Whereas international guidelines encourage deescalation of adjuvant treatment in early-stage POLEmut EC, data regarding safety in POLEmut patients with unfavorable characteristics are still under investigation. On the other hand, the spread of comprehensive genome profiling programs has underscored the need to interpret POLE variants not considered to be hotspots. METHODS: This study provides a comprehensive analysis of 596 sequenced patients with EC. The genomic landscape of POLEmut EC was compared with cases harboring nonhotspot POLE mutations within the exonuclease domain. Additionally, the genomic characteristics of multiple classifiers, as well as those exhibiting unfavorable histopathological and clinical features, were examined. RESULTS: No significant genomic differences were observed among patients with POLEmut EC when comparing multiple classifiers to not-multiple classifiers or those with unfavorable clinical features. However, the tumor mutational burden differed in both comparisons, whereas the percentage of C>G mutations only differed in the comparison based on clinical features. Specific POLE mutations, even if not considered to be hotspots, have genomic features comparable to POLEmut. CONCLUSIONS: The present findings confirm the absence of significant genomic differences among POLEmut patients regardless of multiple-classifier status or association with high-risk clinical features. Prognostic data will be essential to elucidate the clinical significance of POLE mutations not classified as hotspots that exhibit genomic characteristics similar to those in POLEmut patients.
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids Eleonora Cesari, Alessandra Ciucci, Marco Pieraccioli, Cinzia Caggiano, Camilla Nero, Davide Bonvissuto, Francesca Sillano, Marianna Buttarelli, Alessia Piermattei, Matteo Loverro, Floriana Camarda, Viviana Greco, Maria De Bonis, Angelo Minucci, Daniela Gallo, Andrea Urbani, Giuseppe Vizzielli, Giovanni Scambia, Claudio Sette Journal of Experimental and Clinical Cancer Research, 2023
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial Sandro Pignata, Giovanni Scambia, Clorinda Schettino, Laura Arenare, Carmela Pisano, Davide Lombardi, Ugo De Giorgi, Claudia Andreetta, Saverio Cinieri, Carmine De Angelis, Domenico Priolo, Claudia Casanova, Marta Rosati, Filippo Greco, Elena Zafarana, Ilaria Schiavetto, Serafina Mammoliti, Sabrina Chiara Cecere, Vanda Salutari, Simona Scalone, Alberto Farolfi, Marilena Di Napoli, Domenica Lorusso, Piera Gargiulo, Daniela Califano, Daniela Russo, Anna Spina, Rossella De Cecio, Paolo Chiodini, Francesco Perrone, Valentina Accinno, Chiara Altavilla, Claudia Andreetta, Giovanna Antonelli, Laura Arenare, Grazia Artioli, Francesco Avola, Bonifacio Barbara, Valentina Barbato, Michele Bartoletti, Simona Bevilacqua, Roberto Bordonaro, Oriana Borghese, Gaetano Buonfanti, Daniela Califano, Floriana Camarda, Giuliana Canzanella, Vittoria Carbone, Maria Rita Carbone, Giulia Carlo Stella, Claudia Casanova, Chiara Cassani, Fabrizio Castagna, Monica Cattaneo, Sabrina Chiara Cecere, Paolo Chiodini, Margherita Cinefra, Saverio Cinieri, Nicoletta Colombo, Serena Corsetti, Monia Dall'Agata, Maria D'Amico, Gennaro Daniele, Carmine De Angelis, Rossella De Cecio, Ugo De Giorgi, Elvira De Marino, Giovanni De Matteis, Sabino De Placido, Gabriella Del Bene, Antonia Del Giudice, Francesca Del Monte, Michele Del Sesto, Marilena Di Napoli, Maddalena Donini, Giuliana Drudi, Gianluca Falcone, Alberto Farolfi, Adolfo Favaretto, Giulia Ferrera, Manuela Florio, Valeria Forestieri, Maria Stella Gallo, Ciro Gallo, Piera Gargiulo, Francesca Garibaldi, Fabiana Gerevini, Viola Ghizzoni, Maria Olga Giganti, Anna Gimigliano, Elena Giudice, Nicoletta Gnocchi, Adriano Gravina, Filippo Greco, Stefano Greggi, Maria Laura Iaia, Annalisa Ilardi, Gelsomina Iovine, Gabriella Ippoliti, Giulia Irollo, Ilenia Isidori, Mariateresa Lapresa, Giuseppe Lavenia, Davide Lombardi, Laura Longhitano, Domenica Lorusso, Bortot Lucia, Gabriella Luzi, Serafina Mammoliti, Sara Mariano, Valentina Marino, Giovanna Marrapese, Marilena Martino, Roberta Matocci, Enrica Mazzoni, Daniela Mercuri, Maria Mirto, Giovanna Mollo, Abbondanza Montinaro, Marta Moscatelli, Anna Maria Mosconi, Lucia Musacchio, Nicoletta Nanni, Pamela Natalucci, Milena Sabrina Nicoloso, Michele Orditura, Gabriella Maria Parma, Rodolfo Passalacqua, Michela Pelone, Maria Teresa Perri, Francesco Perrone, Bruno Perrucci, Alessandra Piancastelli, Maria Carmela Piccirillo, Antonio Piccolo, Sandro Pignata, Carmela Pisano, Domenico Priolo, Stefania Rapisardi, Giorgia Ravaglia, Teresa Ribecco, Caterina Ricci, Marianna Roccio, Fiorella Romano, Marta Rosati, Daniela Russo, Vanda Salutari, Daniela Sambataro, Alfonso Savio, Ada Sbriglia, Cono Scaffa, Simona Scalone, Giovanni Scambia, Clorinda Schettino, Ilaria Schiavetto, Concetta Sergi, Francesca Sgandurra, Roberto Sorio, Anna Spina, Stefano Stabile, Gianna Tabaro, Margherita Tambaro, Stefano Tamberi, Angelica Tecchiato, Angela Maria Trujillo, Eleonora Zaccarelli, Elena Zafarana Lancet Oncology, 2023
Recent progress in the use of pharmacotherapy for endometrial cancer Elena Giudice, Vanda Salutari, Caterina Ricci, Camilla Nero, Maria Vittoria Carbone, Lucia Musacchio, Viola Ghizzoni, Maria Teresa Perri, Floriana Camarda, Francesca Tronconi, Domenica Lorusso, Giovanni Scambia Expert Opinion on Pharmacotherapy, 2023
Advanced and recurrent endometrial cancer: State of the art and future perspectives Francesca Tronconi, Camilla Nero, Elena Giudice, Vanda Salutari, Lucia Musacchio, Caterina Ricci, Maria Vittoria Carbone, Viola Ghizzoni, Maria Teresa Perri, Floriana Camarda, Marica Gentile, Rossana Berardi, Giovanni Scambia, Domenica Lorusso Critical Reviews in Oncology Hematology, 2022
Management of single pulmonary metastases from colorectal cancer: State of the art Marco Chiappetta, Lisa Salvatore, Maria Teresa Congedo, Maria Bensi, Viola De Luca, Leonardo Petracca Ciavarella, Floriana Camarda, Jessica Evangelista, Vincenzo Valentini, Giampaolo Tortora, Stefano Margaritora, Filippo Lococo World Journal of Gastrointestinal Oncology, 2022
PARP Inhibitors Resistance: Mechanisms and Perspectives Elena Giudice, Marica Gentile, Vanda Salutari, Caterina Ricci, Lucia Musacchio, Maria Vittoria Carbone, Viola Ghizzoni, Floriana Camarda, Francesca Tronconi, Camilla Nero, Francesca Ciccarone, Giovanni Scambia, Domenica Lorusso Cancers, 2022
Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives Elena Giudice, , Floriana Camarda, , Vanda Salutari, , Caterina Ricci, , Camilla Nero, , Maria Vittoria Carbone, , Viola Ghizzoni, , Lucia Musacchio, , Chiara Landolfo, , Maria Teresa Perri, , Giovanni Scambia, , , Domenica Lorusso, , and European Oncology and Haematology, 2021
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study Alessandro Parisi, Alessio Cortellini, Katia Cannita, Olga Venditti, Floriana Camarda, Maria Alessandra Calegari, Lisa Salvatore, Giampaolo Tortora, Daniele Rossini, Marco Maria Germani, Alessandra Boccaccino, Emanuela Dell’Aquila, Claudia Fulgenzi, Daniele Santini, Michele De Tursi, Nicola Tinari, Pietro Di Marino, Pasquale Lombardi, Susana Roselló Keränen, Marisol Huerta Álvaro, Ina Valeria Zurlo, Domenico Cristiano Corsi, Alessandra Emiliani, Nicoletta Zanaletti, Teresa Troiani, Pasquale Vitale, Riccardo Giampieri, Filippo Merloni, Mario Alberto Occhipinti, Paolo Marchetti, Michela Roberto, Federica Mazzuca, Michele Ghidini, Alice Indini, Ingrid Garajova, Federica Zoratto, Simona Delle Monache, Giampiero Porzio, Corrado Ficorella Cancers, 2020
